Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study
暂无分享,去创建一个
C. Caracta | E. G. Gil | A. Kirsten | R. Mroz | J. Beier | R. Segarra | F. Chuecos | E. Gil
[1] J. Murray,et al. Personalized medicine: been there, done that, always needs work! , 2012, American journal of respiratory and critical care medicine.
[2] H. Chrystyn,et al. P209 Impact of Patient Satisfaction with Their Maintenance Inhaler on Treatment Compliance and Health Outcomes in Chronic Obstructive Pulmonary Disease: An Analysis of Real-World Clinical Practise in Europe , 2012, Thorax.
[3] Hsien-Ho Lin,et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials , 2012, Thorax.
[4] E. G. Gil,et al. Preference, satisfaction and critical errors with Genuair® and HandiHaler® in patients with COPD , 2012 .
[5] N. Leidy,et al. Quantifying The Severity Of Respiratory Symptoms Of Chronic Obstructive Pulmonary Disease (COPD): Performance Properties Of The EXAcerbations Of Chronic Pulmonary Disease Tool - Respiratory Symptoms (E-RS) In 3 Randomized Controlled Trials , 2012, ATS 2012.
[6] C. Caracta,et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. , 2012, Pulmonary pharmacology & therapeutics.
[7] E. Kerwin,et al. Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I) , 2012, COPD.
[8] E. Bateman,et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study , 2012, European Respiratory Journal.
[9] H. Magnussen,et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. , 2012, Chest.
[10] P. Poole,et al. Tiotropium versus placebo for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.
[11] B. Celli,et al. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation , 2011, European Respiratory Journal.
[12] E. Kerwin,et al. ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide , 2011 .
[13] E. Bateman,et al. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN , 2011 .
[14] M. Cazzola,et al. Night-time symptoms: a forgotten dimension of COPD , 2011, European Respiratory Review.
[15] P. Enright,et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.
[16] C. Caracta,et al. Nighttime Symptoms Of COPD In A Clinical Trial Population: Prevalence And Impact , 2011, ATS 2011.
[17] A. Swensen,et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. , 2011, Respiratory medicine.
[18] M Cazzola,et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study , 2010, European Respiratory Journal.
[19] B. Yawn,et al. Improving adherence with inhaler therapy in COPD , 2010, International journal of chronic obstructive pulmonary disease.
[20] S. Sentellas,et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[21] W. McNicholas,et al. Effects of Salmeterol on Sleeping Oxygen Saturation in Chronic Obstructive Pulmonary Disease , 2009, Respiration.
[22] M. Partridge,et al. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey , 2009, Current medical research and opinion.
[23] Ruben D. Restrepo,et al. Medication adherence issues in patients treated for COPD , 2008, International journal of chronic obstructive pulmonary disease.
[24] M Cazzola,et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. , 2008, Revista portuguesa de pneumologia.
[25] C. Wentworth,et al. Pooled clinical trial analysis of tiotropium safety. , 2006, Chest.
[26] J. V. van Noord,et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. , 2006, Chest.
[27] C. Lenfant,et al. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .
[28] J. Hankinson,et al. Standardisation of spirometry , 2005, European Respiratory Journal.
[29] J. Donohue. Minimal Clinically Important Differences in COPD Lung Function , 2005, COPD.
[30] W. McNicholas,et al. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD , 2004, European Respiratory Journal.
[31] P. Calverley,et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease , 2003, Thorax.
[32] E. Bateman,et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.
[33] R. Pauwels,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. , 2001, Respiratory care.
[34] D. Hudgel,et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. , 1999, Chest.
[35] W. McNicholas,et al. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. , 1993, The American review of respiratory disease.
[36] D. Postma,et al. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. , 1985, Chest.